Brief: Cspc Pharmaceutical Says Syh2059 Powder Gets Clinical Trial Approval In China, U.S.
16/03/2026 12:58
March 16 (Reuters) - CSPC Pharmaceutical Group Ltd 1093.HK: SYH2059 POWDER FOR INHALATION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA SYH2059 POWDER FOR INHALATION OBTAINS FDA CLINICAL TRIAL APPROVAL IN U.S. IN MARCH 2026 Further company coverage: 1093.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CSPC PHARMACEUTICAL
See all newsBrief: CSPC Pharmaceutical Posts CSPC Innovation Pharmaceutical 9M Net Profit Attributable RMB 1.21 Billion
Brief: CSPC Pharmaceutical Publishes Updated Phase III OS Results For Anbenitamab In Her2-Positive Advanced Gastric Cancer
Brief: CSPC Pharmaceutical Says Batoclimab Injection (Enlida) Obtains Drug Registration Certificate From NMPA
Brief: CSPC Pharmaceutical Initiates Phase III Trial Of SYS6043 For Triple-Negative Breast Cancer In China
Factbox: Pharma sector doubles down on AI to slash costs, timelines